The mid-term follow-up study of capecitabine combined with oxaliplatin in the treatment of 26 patients with advanced gastric cancer

Abstract

Objective To investigate the effect of XELOX chemotherapy protocols on the prognosis of patients with advanced gastric cancer. Methods From May 2014 to May 2016, a total of 52 patients with advanced gastric cancer in the Western Branch of the Second Hospital of Shanxi Medical University were selected and divided into control group and study group according to the random number table, with 26 cases in each group.The control group was treated with the FOLFOX chemotherapy protocols, and the study group was treated with the XELOX chemotherapy protocols.All the patients were treated for 3 cycles.After treatment, the clinical efficacy and serum gastrin-17 (GAS-17) levels before and after treatment of the two groups were statistically analyzed.At the end of the treatment and following up until now, the survival rate of the two groups was statistically analyzed. Results The effective rate of the study group (76.92%) was significantly higher than that of the control group (50.00%)(χ2=4.064, P<0.05). After treatment, the serum level of GAS-17 of the two groups decreased compared with before treatment, and which of the study group was lower than that of the control group (t=7.399, P<0.05). The median progression free survival (9.3 months) and median total survival (12.6 months) in the study group were longer than those in the control group(all P<0.05). Conclusion XELOX chemotherapy in the treatment of advanced gastric cancer can effectively reduce the level of serum GAS-17, improve the therapeutic effect and prolong the duration of life of the patients. Key words: Stomach neoplasms; Antineoplastic combined chemotherapy protocols; Capecitabine; Oxaliplatin; Gastrins; Follow-up studies